Clinical guideline: management of gastroparesis.

This clinical guideline reviewed the best approaches for managing gastroparesis, a condition where the stomach empties too slowly, causing nausea, vomiting, bloating, feeling full quickly, and upper abdominal pain. The guideline examined various treatments including dietary changes, medications, electrical stimulation devices, and surgical options. Researchers found that current approved treatments like metoclopramide (a medication) and gastric electrical stimulation (GES) devices don't fully address patient needs. The guideline recommends starting with dietary modifications and oral nutrition support. If that's insufficient, feeding tubes placed in the small intestine may be needed. Medications tested include antiemetics for nausea, prokinetic drugs to speed stomach emptying, and antidepressants for symptom control, though many lack specific testing for gastroparesis. GES devices showed promise in open-label studies for reducing vomiting frequency and need for nutritional supplements. Injecting botulinum toxin into the pyloric valve did not prove effective in controlled trials. Surgery like partial gastrectomy should be reserved for rare, carefully selected cases. Overall, the evidence base remains limited, with most treatments based on small studies without control groups. The guideline emphasizes the need for better therapies and highlights that management should be individualized, addressing nutrition, symptom relief, and blood sugar control in diabetic patients. For those considering acupuncture as a complementary approach for gastroparesis symptoms, consult with a qualified, licensed acupuncturist experienced in digestive disorders.

This American Journal of Gastroenterology clinical guideline synthesizes evidence for gastroparesis management in patients with delayed gastric emptying and characteristic symptoms (nausea, vomiting, early satiety, bloating, upper abdominal pain). The guideline notes current FDA-approved treatments (metoclopramide, GES on humanitarian device exemption) inadequately address clinical needs. Management recommendations follow a stepwise approach: oral dietary modifications, enteral nutrition via jejunostomy if needed, rarely parenteral nutrition. Pharmacologic options include prokinetic agents and antiemetics, though most lack gastroparesis-specific controlled trials. GES demonstrated reduced weekly vomiting frequency and decreased nutritional supplementation requirements in open-label studies. Intrapyloric botulinum toxin injection failed to show efficacy in RCTs. Off-label therapies include domperidone, short-term erythromycin, and centrally-acting antidepressants as symptom modulators. The guideline acknowledges limited evidence base, with most recommendations derived from open-label trials and small patient cohorts. Surgical interventions (partial gastrectomy, pyloroplasty) reserved for select refractory cases. Clinical takeaway emphasizes individualized multimodal management and urgent need for novel effective therapies.